POLB vs. SCLP, MPH, OBI, ORPH, REDX, ETX, TRX, FUM, SBTX, and COS
Should you be buying Poolbeg Pharma stock or one of its competitors? The main competitors of Poolbeg Pharma include Scancell (SCLP), Mereo BioPharma Group plc (MPH.L) (MPH), Ondine Biomedical (OBI), Open Orphan (ORPH), Redx Pharma (REDX), e-therapeutics (ETX), Tissue Regenix Group (TRX), Futura Medical (FUM), SkinBioTherapeutics (SBTX), and Collagen Solutions plc (COS.L) (COS). These companies are all part of the "biotechnology" industry.
Poolbeg Pharma vs.
Scancell (LON:SCLP) and Poolbeg Pharma (LON:POLB) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their media sentiment, valuation, profitability, institutional ownership, earnings, community ranking, dividends, risk and analyst recommendations.
Scancell is trading at a lower price-to-earnings ratio than Poolbeg Pharma, indicating that it is currently the more affordable of the two stocks.
Scancell's return on equity of 98.74% beat Poolbeg Pharma's return on equity.
46.5% of Scancell shares are owned by institutional investors. Comparatively, 1.2% of Poolbeg Pharma shares are owned by institutional investors. 5.0% of Scancell shares are owned by company insiders. Comparatively, 24.7% of Poolbeg Pharma shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
In the previous week, Scancell had 2 more articles in the media than Poolbeg Pharma. MarketBeat recorded 3 mentions for Scancell and 1 mentions for Poolbeg Pharma. Poolbeg Pharma's average media sentiment score of 0.30 beat Scancell's score of 0.26 indicating that Poolbeg Pharma is being referred to more favorably in the news media.
Scancell has a beta of 0.35, meaning that its stock price is 65% less volatile than the S&P 500. Comparatively, Poolbeg Pharma has a beta of 2.11, meaning that its stock price is 111% more volatile than the S&P 500.
Scancell received 187 more outperform votes than Poolbeg Pharma when rated by MarketBeat users. Likewise, 74.50% of users gave Scancell an outperform vote while only 0.00% of users gave Poolbeg Pharma an outperform vote.
Summary
Scancell beats Poolbeg Pharma on 7 of the 12 factors compared between the two stocks.
Get Poolbeg Pharma News Delivered to You Automatically
Sign up to receive the latest news and ratings for POLB and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Poolbeg Pharma Competitors List
Related Companies and Tools
This page (LON:POLB) was last updated on 2/22/2025 by MarketBeat.com Staff
